S&P Futures
4,275.25 -11.25 (-0.26%) Dow Futures
33,922.00 -59.00 (-0.17%) Nasdaq Futures
13,481.25 -42.00 (-0.31%) Russell 2000 Futures
1,993.70 -8.00 (-0.40%) Crude Oil
89.90 -0.60 (-0.66%) Gold
1,768.20 -3.00 (-0.17%)
Glucose Health, Inc. (GLUC)
Chart Events
Performance Outlook
| Previous Close | 0.6400 |
| Open | 0.6400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.6389 - 0.6490 |
| 52 Week Range | 0.4300 - 3.2450 |
| Volume | |
| Avg. Volume | 15,667 |
| Market Cap | 2.95M |
| Beta (5Y Monthly) | 3.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | Aug 22, 2022 - Aug 29, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for GLUC
Related Research
- GLUCOSE HEALTH INCAnalyst Report: AMETEK, Inc.Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm’s sales are made in the United States. The firm’s asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.RatingFair ValueEconomic Moat9 days agoMorningstar
- GlobeNewswire
Glucose Health, Inc. Corporate Update
BENTONVILLE, AR, March 24, 2022 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC Pink: GLUC) ("Company") today provided the following corporate update, in response to requests from shareholders and interested parties for clarification of recent corporate events. John Fieldly, the current Chief Executive Officer of Celsius Holdings, Inc. (Celsius), Hal Kravitz, a current member of the Board of Directors of Celsius, and Gerry David, the former Chief Executive Officer of Celsius, comprised the indepen
- GlobeNewswire
Glucose Health, Inc. Fiscal 2021 Annual Report
BENTONVILLE, AR, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC) ("Company") is pleased to highlight selected financial metrics presented in its Fiscal 2021 Annual Report posted today at OTCMarkets.com. In fiscal 2021, Glucose Health, Inc. more than doubled gross profits, effectively doubled revenue, and achieved the unique status of a debt free, emerging growth, company. Fiscal 2021 Revenue of $953,681 vs. $480,713 for Fiscal 2020 = a 98% increase.Fiscal 2021 Gross Profit of
- GlobeNewswire
Glucose Health, Inc. USPTO Patent Filing Asserts First Use of Nutritional Composition Underlying GLUCODOWN®
BENTONVILLE, AR, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC Pink: GLUC) ("Company") is pleased to advise that a patent application for "Compositions and Methods for Metabolic Health" was filed with the United States Trademark and Patent Office (USPTO) on December 23, 2021, on behalf of the Company. The patent filing discloses a composition of the combination of resistant dextrin, corosolic acid and chromium picolinate, in measures for maintaining and improving health by attenuat
